These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28228799)

  • 41. [Development of DDS Actively to Overcome the Blood-brain Barrier in the Region of Ischemic Stroke].
    Fukuta T; Kogure K
    Yakugaku Zasshi; 2020; 140(8):1007-1012. PubMed ID: 32741858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?
    Fathi S; Oyelere AK
    Future Med Chem; 2016 Nov; 8(17):2091-2112. PubMed ID: 27774793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape.
    Alamoudi K; Martins P; Croissant JG; Patil S; Omar H; Khashab NM
    Nanomedicine (Lond); 2017 Jun; 12(12):1421-1433. PubMed ID: 28524721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liposomal drug delivery systems--clinical applications.
    Goyal P; Goyal K; Vijaya Kumar SG; Singh A; Katare OP; Mishra DN
    Acta Pharm; 2005 Mar; 55(1):1-25. PubMed ID: 15907221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advantages of liposomal delivery systems for anthracyclines.
    Allen TM; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):5-15. PubMed ID: 15717735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics.
    Mattern-Schain SI; Fisher RK; West PC; Grimsley LB; Harris TM; Grandas OH; Best MD; Mountain DJH
    Chem Phys Lipids; 2019 Jan; 218():149-157. PubMed ID: 30582896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Size dependent variations of phospholipid based vesicular drug carriers in systemic drug activity.
    Mukherjee B; Mondal L; Chakraborty S; Paul P; Choudhury A; Bhattacharya S; Hossain CM
    Curr Pharm Biotechnol; 2015; 16(4):380-91. PubMed ID: 25658382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Binding and interstitial penetration of liposomes within avascular tumor spheroids.
    Kostarelos K; Emfietzoglou D; Papakostas A; Yang WH; Ballangrud A; Sgouros G
    Int J Cancer; 2004 Nov; 112(4):713-21. PubMed ID: 15382056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liposomes for brain delivery.
    Lai F; Fadda AM; Sinico C
    Expert Opin Drug Deliv; 2013 Jul; 10(7):1003-22. PubMed ID: 23373728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
    Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
    ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
    Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
    J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracellular barriers to non-viral gene transfer.
    Lechardeur D; Lukacs GL
    Curr Gene Ther; 2002 May; 2(2):183-94. PubMed ID: 12109215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonviral vectors in the new millennium: delivery barriers in gene transfer.
    Nishikawa M; Huang L
    Hum Gene Ther; 2001 May; 12(8):861-70. PubMed ID: 11387052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist.
    Allon N; Saxena A; Chambers C; Doctor BP
    J Control Release; 2012 Jun; 160(2):217-24. PubMed ID: 22079949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A remote controlled valve in liposomes for triggered liposomal release.
    Koçer A
    J Liposome Res; 2007; 17(3-4):219-25. PubMed ID: 18027242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution.
    O'Mahony AM; Godinho BM; Cryan JF; O'Driscoll CM
    J Pharm Sci; 2013 Oct; 102(10):3469-84. PubMed ID: 23893329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liposomal Drug Delivery System for Cancer Therapy: Advancement and Patents.
    Jha S; Sharma PK; Malviya R
    Recent Pat Drug Deliv Formul; 2016; 10(3):177-183. PubMed ID: 27712569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.